REGISTERED NUMBER: 08867450 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 March 2025

for

Bromage Urology Limited

Page

Balance Sheet

1

Notes to the Financial Statements

2

FIXED ASSETS

Tangible assets

4

160

320

CURRENT ASSETS

Debtors

5

-

8,164

Cash at bank

298,773

349,557

298,773

357,721

CREDITORS

Amounts falling due within one year

6

125,772

182,065

NET CURRENT ASSETS

173,001

175,656

TOTAL ASSETS LESS CURRENT LIABILITIES

173,161

175,976

PROVISIONS FOR LIABILITIES

7

30

61

NET ASSETS

173,131

175,915

CAPITAL AND RESERVES

Called up share capital

8

4

4

Retained earnings

173,127

175,911

SHAREHOLDERS' FUNDS

173,131

175,915

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 11 November 2025 and were signed on its behalf by:

Dr S J Bromage - Director

1.	STATUTORY INFORMATION

Bromage Urology Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

08867450

Registered office:

SPACES Manchester

Peter House, Oxford Street

Manchester

M1 5AN

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment

-

25% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4.	TANGIBLE FIXED ASSETS

Computer

equipment

£

COST

At 1 April 2024

and 31 March 2025

1,740

DEPRECIATION

At 1 April 2024

1,420

Charge for year

160

At 31 March 2025

1,580

NET BOOK VALUE

At 31 March 2025

160

At 31 March 2024

320

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Trade debtors

-

8,164

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Tax

27,784

25,503

Directors' current accounts

96,548

155,242

Accrued expenses

1,440

1,320

125,772

182,065

7.	PROVISIONS FOR LIABILITIES

31.3.25

31.3.24

£

£

Deferred tax

30

61

Deferred

tax

£

Balance at 1 April 2024

61

Utilised during year

(31

)

Balance at 31 March 2025

30

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.3.25

31.3.24

value:

£

£

1

Ordinary A

£1

1

1

1

Ordinary B

£1

1

1

1

Ordinary C

£1

1

1

1

Ordinary D

£1

1

1

4

4

9.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 March 2025 and 31 March 2024:

31.3.25

31.3.24

£

£

Dr S J Bromage and Mrs E J Bromage

Balance outstanding at start of year

(155,242

)

(76,268

)

Amounts advanced

155,242

80,002

Amounts repaid

(96,548

)

(158,976

)

Amounts written off

-

-

Amounts waived

-

-

Balance outstanding at end of year

(96,548

)

(155,242

)

10.	ULTIMATE CONTROLLING PARTY

The controlling party is the directors.